Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter R Ebeling

Showing results (21-30 of 379) with videos related to

Pageof 38
Sort By:
The Journal of Clinical Endocrinology and Metabolism|May 8, 2009
Approach to the patient with transplantation-related bone lossPeter R Ebeling
The Medical Journal of Australia|August 12, 2016
Osteoporosis treatment: a missed opportunityFrances Milat, Peter R Ebeling
Rheumatology (Oxford, England)|January 27, 2021
Comment on: Osteosarcopenia: where osteoporosis and sarcopenia collideDavid Scott, Peter R Ebeling
The Medical Journal of Australia|September 19, 2003
Myxoedema and a lost wedding ringAndrei Catanchin, Peter R Ebeling
F1000 Medicine Reports|October 16, 2010
Recent advances in managing osteoporosisClaudia Gagnon, Peter R Ebeling
International Journal of Environmental Research and Public Health|March 13, 2019
Vitamin D and Public HealthDavid Scott, Peter R Ebeling
Calcified Tissue International|August 30, 2025
Early Postmenopausal Fragility Fractures and Elevated IgE: Two Cases Suggesting Hyper-IgE Syndrome and a Novel Adverse Reaction to RomosozumabLucy Collins, Peter R Ebeling
Alimentary Pharmacology & Therapeutics|October 5, 2024
Editorial: Inflammation and Not Glucocorticoid Therapy is the Key Driver of Fracture Risk in IBDDarcy Quinn Holt, Peter R Ebeling
Expert Review of Endocrinology & Metabolism|October 10, 2018
Romosozumab/CDP7851 for the treatment of osteoporosisIe-Wen Sim, Peter R Ebeling
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 8, 2007
Positive effects of intravenous zoledronic acid on bone remodeling and structure: are different effects on osteoblast activity to other oral bisphosphonates responsible?Peter R Ebeling, David B Burr
Pageof 38

Showing results (21-30 of 379) with videos related to

Sort By:
Pageof 38
The Journal of Clinical Endocrinology and Metabolism|May 8, 2009
Approach to the patient with transplantation-related bone lossPeter R Ebeling
The Medical Journal of Australia|August 12, 2016
Osteoporosis treatment: a missed opportunityFrances Milat, Peter R Ebeling
Rheumatology (Oxford, England)|January 27, 2021
Comment on: Osteosarcopenia: where osteoporosis and sarcopenia collideDavid Scott, Peter R Ebeling
The Medical Journal of Australia|September 19, 2003
Myxoedema and a lost wedding ringAndrei Catanchin, Peter R Ebeling
F1000 Medicine Reports|October 16, 2010
Recent advances in managing osteoporosisClaudia Gagnon, Peter R Ebeling
International Journal of Environmental Research and Public Health|March 13, 2019
Vitamin D and Public HealthDavid Scott, Peter R Ebeling
Calcified Tissue International|August 30, 2025
Early Postmenopausal Fragility Fractures and Elevated IgE: Two Cases Suggesting Hyper-IgE Syndrome and a Novel Adverse Reaction to RomosozumabLucy Collins, Peter R Ebeling
Alimentary Pharmacology & Therapeutics|October 5, 2024
Editorial: Inflammation and Not Glucocorticoid Therapy is the Key Driver of Fracture Risk in IBDDarcy Quinn Holt, Peter R Ebeling
Expert Review of Endocrinology & Metabolism|October 10, 2018
Romosozumab/CDP7851 for the treatment of osteoporosisIe-Wen Sim, Peter R Ebeling
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 8, 2007
Positive effects of intravenous zoledronic acid on bone remodeling and structure: are different effects on osteoblast activity to other oral bisphosphonates responsible?Peter R Ebeling, David B Burr
Pageof 38